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Abstract
Although the formation of a covalent enzyme-cleaved DNA complex is a prerequisite
for the essential functions of topoisomerase II, this reaction intermediate has the potential to destabilize the genome. Consequently, all known eukaryotic type II enzymes
maintain this complex at a low steady-state level. Recently, however, a novel topoisomerase II was discovered in Paramecium bursaria chlorella virus-1 (PBCV-1) that has
an exceptionally high DNA cleavage activity [Fortune et al. (2001) J. Biol. Chem. 276,
24401-24408]. If robust DNA cleavage is critical to the physiological functions of chlorella virus topoisomerase II, then this remarkable characteristic should be conserved
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throughout the viral family. Therefore, topoisomerase II from Chlorella virus Marburg-1
(CVM-1), a distant family member, was expressed in yeast, isolated, and characterized.
CVM-1 topoisomerase II is 1058 amino acids in length, making it the smallest known
type II enzyme. The viral topoisomerase II displayed a high DNA strand passage activity and a DNA cleavage activity that was ~50-fold greater than that of human topoisomerase IIα. High DNA cleavage appeared to result from a greater rate of scission rather
than promiscuous DNA site utilization, inordinately tight DNA binding, or diminished
religation rates. Despite the fact that CVM-1 and PBCV-1 topoisomerase II share ~67%
amino acid sequence identity, the two enzymes displayed clear differences in their DNA
cleavage specificity/site utilization. These findings suggest that robust DNA cleavage
is intrinsic to the viral enzyme and imply that chlorella virus topoisomerase II plays a
physiological role beyond the control of DNA topology.

The topological state of the genetic material profoundly influences a
number of critical nuclear processes including DNA replication, transcription, recombination, and mitosis (1, 2). For example, while global
underwinding of DNA dramatically increases rates of replication, overwinding of the double helix ahead of DNA tracking systems presents a
formidable obstacle to replication fork progression and transcription
(1-5). Furthermore, DNA knots and tangles that accumulate as a result
of recombination and replication must be resolved for the two strands
of the double helix to separate or for chromosomes to segregate during
mitosis (1- 4, 6).
In all living systems, levels of DNA under- and overwinding, knotting,
and tangling are controlled by ubiquitous enzymes known as topoisomerases (1, 4, 7-10). Type II topoisomerases play critical roles in virtually every aspect of DNA metabolism. Although lower eukaryotes such
as yeast and Drosophila express only a single form of topoisomerase II
(11, 12), vertebrates require two closely related isoforms of the enzyme,
topoisomerase IIα and IIβ (13, 14). Topoisomerase IIα is present at low
concentrations in quiescent cells but increases dramatically during periods of cell proliferation (4, 15-19). Therefore, it is believed that this isoform plays fundamental roles in DNA replication and mitotic events such
as chromosome segregation. In contrast, cellular levels of topoisomerase IIβ appear to be independent of proliferative status (4, 15, 20, 21).
Although the precise physiological functions of topoisomerase IIβ have
yet to be defined, it is believed that this isoform is involved in a variety
of ongoing nuclear processes.
Type II topoisomerases control the topological state of DNA by passing an intact double helix through a transient double-stranded break that
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they generate in a separate segment of the genetic material. To regulate
the opening and closing of the “DNA gate” during this process, topoisomerase II forms covalent bonds between its active site tyrosyl residues and
the newly generated DNA termini. These covalent enzyme-DNA complexes are known as cleavage complexes (1, 4, 7, 8, 10, 22).
Type II topoisomerases are essential to the survival of all proliferating cells. However, because these enzymes generate double-stranded
DNA breaks as a mandatory prerequisite for the strand passage event,
they pose a threat to genomic integrity every time they function (10, 23,
24). Under normal circumstances, topoisomerase II opens and closes
the DNA gate very rapidly. Thus, at any given moment, topoisomerase IIDNA cleavage complexes are present at low levels and are tolerated by
the cell. However, physiological conditions that increase either the lifetime or the concentration of cleavage complexes convert topoisomerase
II from an essential enzyme to a potent cellular toxin that fragments the
genetic material (25-29).
Because the DNA cleavage activity of topoisomerase II has the potential to destabilize the genome, the enzyme plays a central role in cancer.
While several widely used anticancer drugs act by increasing levels of
enzyme-mediated DNA scission, evidence suggests that the actions of
topoisomerase II may trigger the chromosomal breaks that initiate specific types of leukemia (26, 27, 30-43). The difference between killing malignant cells and initiating cancer probably is related to the physiological levels of enzyme-induced DNA strand breaks. If the numbers of DNA
breaks are sufficiently high, cells become overwhelmed and induce apoptotic or other death pathways. Conversely, if the numbers of breaks are
sublethal, they trigger recombination/repair pathways that under some
circumstances generate cancer-causing chromosomal translocations.
Due to the potentially lethal nature of the topoisomerase II-mediated DNA scission reaction, low levels of DNA cleavage are characteristic of all known eukaryotic type II enzymes (1, 4, 7, 8, 10, 22). Consequently, this feature was believed to be a hallmark of this enzyme
class. Recently, however, a novel type II topoisomerase was discovered
that possesses a dramatically (30-50-fold) higher DNA cleavage activity. The enzyme is encoded by Paramecium bursaria chlorella virus-1
(PBCV-1)1 (44-47). PBCV-1 topoisomerase II is significantly smaller than
1. Abbreviations: PBCV-1, Paramecium bursaria chlorella virus-1; CVM-1, Chlorella virus Marburg-1; PCR, polymerase chain reaction; kDNA, kinetoplast DNA.
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its eukaryotic counterpart due to a large C-terminal deletion, but otherwise displays high amino acid sequence identity. Furthermore, aside
from a robust DNA cleavage activity, the catalytic reaction of the viral
enzyme is in all respects typical of eukaryotic type II topoisomerases.
It is not known what role topoisomerase II plays in the life cycle of
chlorella viruses. The extremely high DNA scission activity of PBCV-1
topoisomerase II suggests that the viral enzyme may play alternative
roles beyond the normal control of DNA topology, such as initiating genetic recombination in the virus or death pathways in the host cell. If robust DNA cleavage is critical to the physiological functions of chlorella
virus topoisomerase II, then this remarkable characteristic should be
evolutionarily maintained throughout this diverse and ancient group
of viruses (48-51). Therefore, recombinant topoisomerase II from Chlorella virus Marburg-1 (CVM-1), a distantly related family member (52),
was expressed in yeast, isolated, and characterized. CVM-1 topoisomerase II displayed a DNA cleavage activity that was even higher than that
seen for the PBCV-1 enzyme. This finding strongly suggests that the high
DNA cleavage activity of the chlorella virus type II topoisomerases is intrinsic to this viral enzyme family and implies that it provides an important physiological benefit for the virus.
Experimental Procedures
Enzymes and Materials.
Negatively supercoiled pBR322 DNA was prepared using a Plasmid
Mega Kit (Qiagen) as described by the manufacturer. Kinetoplast DNA
(kDNA) was isolated from Crithidia fasciculata as described by Englund
et al. (53). [γ-32P]ATP (~5000 Ci/mmol) was obtained from ICN. Etoposide was from Sigma, amsacrine was from Bristol-Myers Squibb, and CP115,953 was from Pfizer. These drugs were stored at 4 °C as 10 or 20
mM stock solutions in 100% DMSO. The pPM231 vector used for expression of viral type II topoisomerases was the gift of Dr. Louise Prakash.
All other chemicals were analytical reagent grade.
Cloning of the CVM-1 Topoisomerase II Gene.
The putative topoisomerase II ORF of 3174 base pairs was amplified
from CVM-1 genomic DNA by the polymerase chain reaction (PCR) with
KOD Hot Start DNA polymerase (Novagen). The following sequences
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were used for the forward and reverse primers, respectively: TACTAACGGATCCAATAAACATGGC and TATGTTTAGGATCCAATTTCAAATG. CVM-1
genomic DNA was denatured at 94 °C for 2 min and subjected to 40 cycles of PCR using the following program: denaturation at 94 °C for 15 s,
annealing at 50 °C for 30 s, and primer extension for 4 min at 68 °C. Following PCR, primers were allowed to extend for an additional 10 min
at 68 °C, and the final product was purified by gel electrophoresis. The
pMP231 vector was digested with BglII and treated with calf intestinal
phosphatase for 1 h. The PCR product was digested with BamHI, ligated
into the vector, and transformed into Escherichia coli TOP10. The CVM-1
topoisomerase II construct was sequenced to confirm the primary structure of the gene. The resultant plasmid, pPMTOP030, was transformed
into Saccharomyces cerevisiae JEL-1Δtop1 by heat shock. The GenBank
accession number for CVM-1 topoisomerase II is AY761524.
Expression and Purification of Recombinant Type II Topoisomerases.
CVM-1 topoisomerase II and PBCV-1 topoisomerase II were expressed
in S. cerevisiae JEL-1Δtop1 and purified by a modification of the procedure of Lavrukhin et al. (44). A detailed protocol for the purification of
CVM-1 topoisomerase II is presented in the Supporting Information that
accompanies this paper. Human topoisomerase IIα was expressed and
purified as described by Kingma et al. (54).

DNA Relaxation.
DNA relaxation reactions were carried out as described by Fortune and
Osheroff (55). Assay mixtures contained 0.05-4 nM CVM-1 topoisomerase II, PBCV-1 topoisomerase II, or human topoisomerase IIα, 1 mM
ATP, and 5 nM negatively supercoiled pBR322 DNA in a total of 20 μL of
DNA relaxation buffer (CVM-1 topoisomerase II and PBCV-1 topoisomerase II, 10 mM Tris-HCl, pH 8.5, 62.5 mM NaCl, 62.5 mM KCl, 0.1 mM
NaEDTA, 2.5 mM MgCl2, and 2.5% glycerol; human topoisomerase IIα,
10 mM Tris-HCl, pH 7.9, 175 mM KCl, 5 mM MgCl2, 0.1 mM NaEDTA, and
2.5% glycerol). Reactions were incubated at 30 °C (CVM-1), 25 °C (PBCV1), or 37 °C (human) for 15 min and stopped by the addition of 3 μL of
stop solution (0.5% SDS, 77 mM EDTA). Proteinase K was added (2 μL
of a 0.8 mg/mL solution), and reactions were incubated for 30 min at 45
°C to digest the enzyme. Samples were mixed with agarose gel loading
buffer (60% sucrose in 10 mM Tris-HCl, pH 7.9) and subjected to electrophoresis in 1% agarose gels in 100 mM Tris-borate, pH 8.3, 2 mM
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EDTA. Gels were stained for 30 min with 0.5 μg/mL ethidium bromide,
and DNA bands were visualized by UV light and were quantified using
an Alpha Innotech digital imaging system (San Leandro, CA).

Decatenation of Kinetoplast DNA (kDNA).
DNA decatenation reactions were carried out as described by Miller et
al. (56). Assay mixtures contained 1 mM ATP, 5 nM kDNA, and 0-20 nM
topoisomerase II in a total of 20 μL of DNA relaxation buffer. Decatenation was initiated by the addition of topoisomerase II, followed by incubation for 30 min at 30 °C (CVM-1), 25 °C (PBCV-1), or 37 °C (human).
Reactions were terminated by the addition of 3 μL of stop solution. Samples were processed and products were quantified as in the preceding
section.
DNA Cleavage.
Plasmid DNA cleavage reactions were based on the procedure of Fortune and Osheroff (55). Unless stated otherwise, reaction mixtures contained 10 nM negatively supercoiled pBR322 DNA in a total of 20 μL of
DNA cleavage buffer (CVM-1 topoisomerase II, 10 mM Tris- HCl, pH 8.5,
120 mM KCl, 0.1 mM NaEDTA, 15 mM MgCl2, and 2.5% glycerol; PBCV-1
topoisomerase II, 10 mM Tris-HCl, pH 8.5, 62.5 mM NaCl, 62.5 mM KCl,
0.1 mM NaEDTA, 2.5 mM MgCl2, and 2.5% glycerol; human topoisomerase IIα, 10 mM Tris-HCl, pH 7.9, 100 mM KCl, 5 mM MgCl2, 0.1 mM
NaEDTA, and 2.5% glycerol). In reactions that optimized DNA cleavage
by CVM-1 topoisomerase II, the pH, MgCl2 concentration, reaction temperature, or KCl concentration was varied. DNA cleavage was initiated
by the addition of topoisomerase II (final enzyme concentrations were
20 nM for CVM-1 and PBCV-1 and 200 nM for human unless stated otherwise). Reaction mixtures were incubated for 6 min at 30 °C (CVM-1),
25 °C (PBCV-1), or 37 °C (human) to establish cleavage/religation equilibria. Cleavage intermediates were trapped by the addition of 2 μL of
1.15% SDS and 2 μL of 115 mM NaEDTA, pH 8.0 (CVM-1 and PBCV-1), or
2 μL of 5% SDS and 2 μL of 250 mM NaEDTA, pH 8.0 (human). Proteinase K was added (2 μL of 0.8 mg/mL), and mixtures were incubated for
30 min at 45 °C to digest the type II enzyme. Samples were mixed with
2 μL of agarose gel loading buffer, heated for 2 min at 45 °C, and subjected to electrophoresis in 1% agarose gels in 40 mM Tris-acetate, pH
8.3, 2 mM EDTA containing 0.5 μg/mL ethidium bromide. DNA cleavage
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was monitored by the conversion of negatively supercoiled plasmid to
linear molecules. DNA bands were quantified by digital imaging as described above. To determine whether DNA cleavage mediated by CVM-1
topoisomerase II was reversible, EDTA (10 mM final concentration, in
lieu of post-SDS addition) was added prior to treatment with SDS. To determine whether cleavage was protein-linked, proteinase K treatment
was omitted.
DNA sites cleaved by CVM-1 topoisomerase II, PBCV-1 topoisomerase
II, or human topoisomerase IIα were mapped as described by O’Reilly
and Kreuzer (57). A linear 4330 bp fragment (HindIII/EcoRI) of pBR322
plasmid DNA singly labeled with [32P]phosphate on the 5′-terminus of
the HindIII site was used as the cleavage substrate. Reaction mixtures
contained 0.35 nM DNA molecules and 60 nM topoisomerase II in 50 μL
of cleavage buffer. Assays were carried out in the absence of compound
or in the presence of 50 μM etoposide, amsacrine, or CP-115,953. Reactions were started by the addition of the enzyme, and the mixtures
were incubated for 10 min at 30 °C (CVM-1), 25 °C (PBCV-1), or 37 °C
(human). Cleavage intermediates were trapped by adding 5 μL of 1.15%
SDS followed by 5 μL of 115 mM NaEDTA (CVM-1 and PBCV-1), or 5 μL of
10% SDS followed by 5 μL of 250 mM NaEDTA, pH 8.0 (human), and the
enzymes were digested with proteinase K (5 μL of a 0.8 mg/mL solution)
for 30 min at 45 °C. Products were precipitated twice in 100% ethanol,
dried, resuspended in 40% formamide, 8.4 mM EDTA, 0.02% bromophenol blue, and 0.02% xylene cyanole FF, and subjected to electrophoresis in 6% acrylamide gels. Gels were fixed in 10% methanol/10% acetic acid for 5 min and dried. DNA cleavage products were visualized on
a Bio-Rad Molecular Imager FX.

Topoisomerase II-DNA Binding.
Topoisomerase II-DNA binding was assessed using a nitrocellulose filterbinding assay. Linear pBR322 DNA radiolabeled with [32P]phosphate was
prepared as described in the DNA Cleavage section. Binding mixtures
contained 5 nM DNA and 10-400 nM topoisomerase II in a total of 20 μL
of DNA binding buffer [10 mM Tris-HCl (CVM-1 topoisomerase II, pH 8.5;
human topoisomerase IIα, pH 7.9), 5 mM KCl, 0.1 mM NaEDTA, and 2.5%
glycerol] and were incubated for 6 min at 30 °C (CVM-1) or 37 °C (human). Nitrocellulose membranes (0.45 μm HA, Millipore) were prepared
by incubation in DNA binding buffer for 10 min. Samples were applied
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to the membranes and filtered in vacuo. Membranes were washed three
times with 1 mL of DNA binding buffer, dried, and submerged in 8 mL of
scintillation fluid (Econo-Safe, Research Products International). Radioactivity remaining on the membranes was quantified using a Beckman
LS 5000 TD scintillation counter. The percent DNA bound to topoisomerase II was determined by the ratio of the radioactivity on the membranes vs that of the input DNA.

DNA Religation.
Topoisomerase II DNA religation was monitored according to the procedure of Robinson and Osheroff (58). Topoisomerase II DNA cleavage/religation equilibria were established as above for plasmid DNA cleavage.
Religation was initiated by shifting reactions from 30 °C (CVM-1) or 37
°C (human) to –5 °C. Reactions were stopped at time points following
the temperature shift by the addition of 2 μL of 1.15% SDS followed by
2 μL of 115 mM NaEDTA, pH 8.0 (CVM-1), or 2 μL of 5% SDS followed by
2 μL of 250 mM NaEDTA, pH 8.0 (human). Samples were processed and
analyzed as described for topoisomerase II plasmid DNA cleavage reactions. Religation was monitored by quantifying the loss of linear DNA.
Results
Because of the potentially mutagenic and lethal effects of topoisomerase II-generated DNA breaks, the enzyme maintains low levels of covalent DNA cleavage complexes throughout its strand passage event (1,
10, 23). This characteristic is an invariant feature of all known eukaryotic type II enzymes. Therefore, it was remarkable when a eukaryoticlike topoisomerase II from chlorella virus PBCV-1 was discovered that
displayed a DNA scission activity ~30 times higher than that of human
topoisomerase IIα (44- 46). The extraordinary DNA cleavage activity of
PBCV-1 topoisomerase II raises questions regarding the physiological
role of this enzyme.
If robust DNA cleavage is critical to the in vivo functions of chlorella
virus topoisomerase II, then this remarkable characteristic should be
maintained throughout the viral family (48-51). Therefore, topoisomerase II from a distantly related chlorella virus, CVM-1, was characterized.
The two viral strains differ in a number of critical aspects. CVM-1 and
PBCV-1 infect different Chlorella species, Pbi and NC64A, respectively,
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and will not attach to the other’s algal host (49, 52). In addition, the
methylation states of CVM-1 and PBCV-1 DNA differ markedly. For example, while 41.9% of the cytosines in the CVM-1 genome exist as 5-methylcytosine, only 1.9% are modified in PBCV-1 (51, 59). Finally, as determined by dot blot analysis, the topoisomerase II genes in these two viral
strains display little cross-reactivity (45). Since CVM-1 and PBCV-1 display considerable divergence, similarities between the type II topoisomerases of these two viruses would imply a strong conservation over the
course of chlorella virus evolution.
Cloning, Expression, and Purification of CVM-1 Topoisomerase II.
Random sequencing of the CVM-1 genome identified an open reading
frame that was predicted to encode a protein with 67% amino acid sequence identity to PBCV-1 topoisomerase II (Figure 1). The putative
CVM-1 topoisomerase II is 1058 amino acids in length as compared to
1531 for human topoisomerase IIα. The major difference between the
two enzymes is that CVM-1 lacks the variable C-terminal domain of eukaryotic topoisomerase II. The amino acid sequence of CVM-1 topoisomerase II is 43% identical to the first 1058 residues of human topoisomerase IIα (Figure 1). Finally, CVM-1 topoisomerase II is three amino
acid residues shorter than the PBCV-1 enzyme, making it the smallest
known type II enzyme.
The predicted CVM-1 topoisomerase II gene was amplified by PCR
and cloned into the galactose-inducible pMP231 expression plasmid to
create pPMTOPO30. S. cerevisiae JEL-1Δtop1 was transformed with pPMTOPO30, and CVM-1 topoisomerase II was expressed and purified to
greater than 95% homogeneity by a procedure similar to that used to
isolate the PBCV-1 type II enzyme (see Supporting Information Figure
S1). The electrophoretic mobility of CVM-1 topoisomerase II on denaturing polyacrylamide gels was consistent with the predicted molecular mass of 120 kDa.
Catalytic Activity of CVM-1 Topoisomerase II.
To determine whether the CVM-1 protein was a type II topoisomerase,
its ability to catalyze double-stranded DNA passage was determined.
First, the relaxation of negatively supercoiled plasmid molecules was
assessed (Figure 2). The recombinant CVM-1 protein displayed a vigorous DNA relaxation activity that was at least 10-fold higher than that
of human topoisomerase IIα and slightly higher than that of PBCV-1
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Figure 1: The amino acid sequences of CVM-1 topoisomerase II (CVM-1), PBCV-1 topoisomerase II (PBCV-1), and human topoisomerase IIα (human) were aligned using the
ClustalW sequence alignment tool provided by the European Bioinformatics Institute
(www.ebi.ac.uk/clustalw). The presumed active site tyrosyl residue of the CVM-1 enzyme is located at position 737. Virtually all of the amino acid residues that are highly
conserved among eukaryotic type II topoisomerases also are present in CVM-1 topoisomerase II. However, the viral type II topoisomerase lacks the C-terminal domain typical of eukaryotic type II enzymes.

topoisomerase II. This finding confirms that the CVM-1 protein is a topoisomerase. However, it does not establish whether it is a type I or a type
II enzyme. While type I topoisomerases relax plasmids by making transient single-stranded DNA breaks and require no high-energy cofactor
(9, 60-65), type II enzymes act by creating double-stranded DNA breaks
and require ATP to carry out strand passage (10, 66-68). Since the CVM-1
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Figure 2: Relaxation of negatively supercoiled pBR322 plasmid DNA by CVM-1 topoisomerase II (top), PBCV-1 topoisomerase II (middle), or human topoisomerase IIα (bottom). DNA relaxation reactions were carried out for 15 min in either the absence of
enzyme (DNA) or the presence of 0.05-4 nM enzyme. Ethidium bromide-stained gels
that are representative of three independent experiments are shown. Negatively supercoiled DNA (form 1, FI) and nicked circular DNA (form 2, FII) are indicated.

enzyme was unable to relax the plasmid in the absence of ATP, it appears
to be a type II topoisomerase (data not shown). To further demonstrate
that the enzyme is topoisomerase II, a second assay, DNA decatenation,
was utilized. Since uncoupling of double-stranded DNA rings requires
a double-stranded DNA passage event, only type II topoisomerases can
catalyze this reaction. As seen in Figure 3, CVM-1 topoisomerase II decatenated kDNA at a higher rate than human topoisomerase IIα and was
as efficient as PBCV-1 topoisomerase II. Furthermore, no decatenation
occurred in the absence of ATP. These findings provide strong evidence
that the CVM-1 enzyme is indeed topoisomerase II.
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Figure 3: Decatenation of kDNA by CVM-1 topoisomerase II. The percent decatenation was determined by quantifying minicircles that were released from kDNA networks by CVM-1 topoisomerase II in the presence (closed circles) or absence (closed
squares) of ATP, by human topoisomerase IIα in the presence of ATP (open circles),
or by PBCV-1 topoisomerase II in the presence of ATP (open squares) and is shown
on the left. Error bars represent the standard deviation of three independent experiments. The gel shown at the right is an ethidium bromide-stained 1% agarose gel
showing kDNA decatenation in the absence of enzyme (DNA), by human topoisomerase IIα (hTIIα), by CVM-1 topoisomerase II (CVM), and by CVM-1 topoisomerase II in
the absence of ATP (-ATP). Reaction mixtures contained 4 nM enzyme. The positions
of the kDNA networks at the origin, as well as those of the released DNA maxicircles
and minicircles, are indicated.

DNA Cleavage Activity of CVM-1 Topoisomerase II.
A distinguishing characteristic of PBCV-1 topoisomerase II is its extraordinarily high DNA cleavage activity. To determine whether this remarkable feature extends to a distantly related chlorella virus, the ability of
CVM-1 topoisomerase II to cleave DNA was optimized (Supporting Information Figure S2) and characterized. The CVM-1 enzyme displayed a
robust DNA scission activity that was dramatically higher than that observed for human topoisomerase IIα (Figure 4). At least 10-fold more
plasmid was cleaved by the viral enzyme than was cleaved by an order
of magnitude more human topoisomerase IIα.
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Figure 4: CVM-1 topoisomerase II displays a robust DNA cleavage activity that is protein-linked and reversible. The ethidium bromide-stained agarose gel shows a 10 nM
negatively supercoiled plasmid DNA control (DNA) and a DNA cleavage reaction carried out in the presence of 200 nM human topoisomerase IIα (hTIIα) or 20 nM CVM-1
topoisomerase II (CVM-1). To determine whether the DNA cleaved by CVM-1 topoisomerase II was protein-linked, proteinase K treatment was omitted (-ProK). Reversibility of the cleavage reaction was determined by adding EDTA to the reaction prior
to SDS treatment (EDTA). Double-stranded DNA cleavage converts negatively supercoiled plasmid (form I, FI) to linear molecules (form III, FIII). The position of nicked
circular DNA (form II, FII) also is indicated. Data are representative of three independent experiments.

CVM-1 topoisomerase II was covalently attached to cleaved DNA molecules (Figure 4), as demonstrated by the decreased electrophoretic
mobility of linearized plasmids when proteinase K treatment was omitted.2 Removal of the required Mg(II) by the addition of EDTA reversed
DNA cleavage, converting linear plasmids back to negatively supercoiled
molecules (Figure 4). This finding demonstrates that CVM-1 topoisomerase II remains active following DNA cleavage and that the high levels
of scission are not due to the formation of a dead-end cleavage complex.
2. The electrophoretic shift of the linearized plasmid DNA observed in the absence of proteinase K was considerably less pronounced than previously seen for DNA cleaved by other type
II enzymes. The DNA cleavage complex generally is shifted to the gel origin due to the strong
interaction of topoisomerase II with the gel matrix. As determined by Coomassie staining of
the gel, CVM-1 topoisomerase II co-localized with the linearized plasmid molecules (data
not shown). This finding confirms that the viral enzyme is covalently attached to the cleaved
DNA. At the present time, it is not known why CVM-1 topoisomerase II displays little affinity
for agarose gel as compared to other type II enzymes.
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Figure 5: DNA cleavage by type II topoisomerases. The ability of CVM-1 topoisomerase II (closed circles), PBCV-1 topoisomerase II (open squares), and human topoisomerase IIα (open circles) to cleave negatively supercoiled pBR322 plasmid DNA was determined. A range of enzyme:DNA ratios was examined at a constant concentration of
10 nM plasmid. DNA cleavage mediated by CVM-1 topoisomerase II also is shown in the
inset. Cleavage is expressed as the percentage of circular DNA substrate converted to
linear molecules at equilibrium. Error bars represent the standard deviation of three
independent experiments.

To further characterize the DNA scission activity of CVM-1 topoisomerase II, cleavage was quantified over a range of enzyme concentrations and compared to that of human topoisomerase IIα and PBCV-1
topoisomerase II (Figure 5). At an enzyme:plasmid ratio of 2:1, CVM-1
topoisomerase II cleaved approximately half of the DNA molecules. This
stands in marked contrast to human topoisomerase IIα, which cleaved
less than 5% of the plasmid substrate at a enzyme:plasmid ratio of 20:1.
The DNA scission activity of CVM-1 topoisomerase II was comparable to
or slightly higher than that of the PBCV-1 enzyme. Taken together, these
results demonstrate that CVM-1 topoisomerase II has an intrinsic DNA
cleavage activity that is extremely high and is at least 50 times greater
than that of human topoisomerase IIα.
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Site-Specific DNA Cleavage by CVM-1 Topoisomerase II.
DNA cleavage was monitored at the site-specific level by utilizing a singly
end labeled linear plasmid substrate. Type II enzymes, including human
topoisomerase IIα, typically cut DNA at a limited number of prominent
sites (Figure 6, left). Anticancer drugs such as etoposide often enhance

Figure 6: Distribution of
topoisomerase II-mediated DNA
cleavage sites on a linear DNA
substrate. A singly end labeled 4330
bp fragment of pBR322 (1.5 nM) was
employed. The autoradiogram at the
left shows a DNA control (DNA) and
cleavage in the presence of 60 nM
human topoisomerase IIα (hTIIα),
60 nM human topoisomerase IIα plus
50 μM etoposide (hTIIα/Etop), 60
nM PBCV-1 topoisomerase II (PBCV1), or 60 nM CVM-1 topoisomerase
II (CVM-1). The autoradiogram at
the right shows a DNA control (DNA)
and cleavage in the presence of 60
nM CVM-1 topoisomerase II with
no drug (CVM-1) or enzyme plus
50 μM etoposide (Etop), amsacrine
(Amsa), or CP-115, 953 (953). Data are
representative of three independent
experiments.
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DNA scission at these same sites. However, the pronounced rise in strand
breaks induced by these agents more often results from a dramatic increase in the number of sites cut by the enzyme. For example, inclusion
of 50 μM etoposide in cleavage assays converts topoisomerase IIα from
an enzyme that cuts DNA at a limited array of sites to one that cleaves
at a far greater number of sequences.
As a first step toward understanding the basis for the robust DNA
cleavage activity of CVM-1 topoisomerase, sites of DNA scission were
mapped. Several aspects of CVM-1 topoisomerase II-mediated DNA
cleavage were striking (Figure 6, left). First, the viral enzyme cut DNA
at a modest number of sites and did not display the promiscuity associated with drug-enhanced DNA scission. Second, virtually every site
cleaved by CVM-1 topoisomerase II had a counterpart (although usually considerably weaker) that was cleaved by human topoisomerase
IIα. Third, despite the fact that CVM-1 and PBCV-1 topoisomerase II cut
DNA at high levels and with a similar sequence specificity, differences
in site utilization were observed.
Susceptibility of CVM-1 Topoisomerase II to Anticancer Drugs.
Of the known eukaryotic-like type II topoisomerases, the only enzyme
that does not display a high susceptibility to anticancer agents is PBCV-1
topoisomerase II (45). Therefore, the effects of anticancer agents on the
DNA cleavage activity of CVM-1 topoisomerase II were assessed. Three
structurally and mechanistically diverse compounds were employed,
etoposide, amsacrine, and the quinolone CP- 115,953 (10, 23, 69-73).
Whereas etoposide and CP-115,953 bind DNA poorly (if at all), amsacrine is a strong DNA intercalator. Furthermore, while etoposide and amsacrine increase levels of DNA scission primarily by inhibiting the ability of topoisomerase II to ligate cleaved molecules, CP- 115,953 appears
to act primarily by enhancing the forward rate of scission.
Drugs had relatively little effect on global cleavage of supercoiled plasmid molecules by CVM-1 topoisomerase II (data not shown). Using the
more sensitive site-specific assay, etoposide and amsacrine enhanced
cleavage at a limited number of sites (Figure 6, right). In contrast, no increase in cleavage was observed at any site in reactions that contained
CP-115,953 (Figure 6, right). These results suggest that low sensitivity
to DNA cleavage-enhancing anticancer drugs is a characteristic feature
of type II topoisomerases from chlorella viruses.
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Figure 7: Topoisomerase II-DNA binding. The percent binding of radiolabeled linear
pBR322 DNA to CVM-1 topoisomerase II (closed circles) or human topoisomerase IIα
(open circles) was determined by the ratio of cpm retained on a nitrocellulose filter
vs the input amount of radioactivity. Error bars represent the standard deviation of
three independent experiments.

Binding of DNA to CVM-1 Topoisomerase II.
Several factors may contribute to the robust DNA cleavage activity of
CVM-1 topoisomerase II. Levels of DNA cleavage can be raised by increased DNA binding, enhanced rates of DNA scission, or diminished
rates of DNA religation.
To determine whether the high levels of DNA cleavage mediated by
the viral enzyme are related to a greater affinity for DNA, the ability of
CVM-1 topoisomerase II to bind linear DNA molecules was determined.
As seen in Figure 7, the affinity of the viral enzyme for DNA appeared
to be slightly higher (<2-fold) than that of human topoisomerase IIα.
This minor increase in DNA binding, however, cannot account for the
dramatic difference in the level of DNA cleavage mediated by these two
enzymes.

Religation of Cleaved DNA by CVM-1 Topoisomerase II.
At the present time, no assays are available that directly measure the
forward rate of topoisomerase II-mediated DNA cleavage. However,
a number of topoisomerase II-targeted anticancer drugs increase
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Figure 8: DNA religation mediated by CVM-1 topoisomerase II (closed circles) or human topoisomerase IIα (open circles). The DNA cleavage/religation equilibrium was
established as described for plasmid DNA cleavage reactions, and religation was initiated by shifting samples to -5 °C. The DNA cleavage observed at equilibrium for each
enzyme was set to 100% at time zero. Error bars represent the standard deviation of
three independent experiments.

enzyme-generated DNA breaks by inhibiting the ability of topoisomerase II to religate cleaved DNA molecules (10, 23, 69, 74). Therefore, the
rate of DNA religation mediated by CVM-1 topoisomerase II was determined (Figure 8). On the basis of the t½ for religation, the apparent firstorder rate constant for DNA religation mediated by CVM-1 topoisomerase II was ~3-fold slower than that of human topoisomerase IIα. Once
again, it does not appear that this difference can account for the ~50fold greater DNA cleavage observed for CVM-1 topoisomerase II. While
differences in the ability of the viral enzyme to bind and religate DNA
appear to contribute to the high levels of DNA scission, the above results
suggest that the robust DNA cleavage activity of CVM-1 topoisomerase
II is caused primarily by a greater rate of DNA scission.
Discussion
Recently, the first type II topoisomerase was isolated from a virus that
infects eukaryotic cells (44). In most respects, PBCV-1 topoisomerase
II is similar to its eukaryotic counterparts. However, the viral enzyme
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displays a remarkably high DNA cleavage activity, ~30-fold greater than
that of previously characterized type II topoisomerases (45, 46). This unexpected finding significantly impacts the dogma that type II enzymes
inherently maintain low levels of cleavage complexes, and led us to ask
whether high DNA scission is unique to the PBCV-1 enzyme or is a conserved feature of chlorella viruses. Therefore, topoisomerase II from
CVM- 1, a chlorella virus that is distantly related to PBCV-1, was isolated
and characterized (52).
CVM-1 topoisomerase II is 1058 amino acids in length (3 amino acids
shorter than the PBCV-1 enzyme), making it the smallest known type II
topoisomerase. The enzyme displays a vigorous double-stranded DNA
strand passage activity and cleaves DNA at levels that exceed those of
PBCV-1 topoisomerase II. High DNA cleavage does not result from an inordinately tight binding between the viral enzyme and DNA or a diminished ability to religate cleaved strands. Rather, it is suggested that high
cleavage is caused primarily by an increase in the forward rate of DNA
scission. These findings are consistent with the high overall catalytic activity of CVM-1 topoisomerase II. On the basis of the above, we conclude
that robust DNA cleavage is a fundamental property of type II enzymes
from chlorella viruses.
Of the known viral families that infect eukaryotic hosts, members of
only four encode a topoisomerase of any kind (75). Three of the four, including Phycodnaviridae (which contains the chlorella viruses) (49, 51,
76), Asfarviridae (which contains African swine fever virus) (77, 78),
and Iridoviridae (which contains Chilo iridescent virus) (79), have open
reading frames that are homologous to eukaryotic type II topoisomerases (75). Like chlorella virus topoisomerase II, the predicted type II enzymes from African swine fever virus and Chilo iridescent virus (1191
and 1132 amino acids in length, respectively) are much smaller than eukaryotic topoisomerase II (77-79). The fourth virus family, Poxviridae
(which contains vaccinia virus), encodes a type IB topoisomerase (65,
80-82). Vaccinia topoisomerase is by far the smallest known type I enzyme (314 amino acids) and possesses a DNA cleavage activity that is
both greater and considerably more site-specific than those of any other
characterized type IB topoisomerase (65, 82-84).
It is notable that these four viral families are believed to be “monophyletic,” in the sense that they are evolutionarily related to the exclusion
of all other viruses (75). These families all have large double-stranded
DNA genomes that are characterized by hairpin telomeres or circularly
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permuted ends (85-89). In addition, they encode many of the proteins
required for viral replication, and replicate in part or entirely in the host
cytoplasm (49, 51, 76, 87, 88, 90, 91).
It is not known why these viruses encode their own topoisomerases.
However, the high DNA cleavage activity of the chlorella virus type II and
poxvirus type I topoisomerases suggest that these enzymes play a role
in the viral life cycle that extends beyond the control of DNA topology.
For example, it has been proposed that vaccinia virus topoisomerase is
involved in resolving hairpin telomeres during replication (92). In addition, these enzymes may play a role in initiating viral DNA recombination or in fragmenting the host genome. Alternatively, the high DNA
cleavage activity of chlorella virus topoisomerase II may reflect some
unique aspect of the viral environment, such as the high DNA methylation of the CVM-1 genome.
Finally, the high amino acid sequence identity and other properties
shared by chlorella virus and eukaryotic topoisomerase II make CVM-1
and PBCV-1 topoisomerase II ideal models for studying the DNA cleavage reaction of type II enzymes. Although topoisomerase II-mediated
DNA scission and ligation play important roles in upholding genomic
stability, the low DNA cleavage activity of eukaryotic type II enzymes
has made it impossible to address many questions regarding these critical reactions (24). The extraordinarily high steady-state concentration
of cleavage complexes maintained by chlorella virus topoisomerase II
provides a unique tool to address these vital issues.
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Supporting Information
Supporting information details the procedure used to isolate recombinant CVM-1 topoisomerase II. A silver-stained SDS-polyacrylamide gel containing purified recombinant
CVM-1 topoisomerase II, PBCV-1 topoisomerase II, and human topoisomerase IIα is included in the supporting information as Figure S1 to demonstrate purity of the sample. Also, optimization of the MgCl2 concentration, temperature, pH, and KCl concentration for DNA cleavage mediated by CVM-1 topoisomerase II is shown in Figure S2.
This material follows the References.
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Purification of CVM-1 Topoisomerase II. Enzyme purification was carried out by a
modification of the protocol of Lavrukhin et al. (44). All steps were carried out at 4 °C. Cells
from 2-Liter yeast cultures were centrifuged for 10 min at 4,000 g, resuspended in 35 mL of
buffer A (15 mM sodium phosphate, pH 6.8, 500 mM NaCl, 10% glycerol, 1 mM EDTA, 1 mM
EGTA, 0.5 mM DTT, 0.2 mM PMSF, 1 µg/mL pepstatin, 1 µg/mL leupeptin), and disrupted by
bead beating. Cell debris was removed by centrifugation at 20,000 g for 10 min. Nucleic acids
were precipitated by the slow addition of 5% (w/v) polyethylenimine (Sigma) to the
supernatant, with stirring to 0.1% final concentration. Stirring was continued for 30 min after all
the polyethylenimine was added. The suspension was centrifuged at 20,000 g for 10 min, the
pellet was resuspended, and (NH4)2SO4 was added slowly with stirring to the supernatant to
35% saturation. The suspension was stirred for an additional 30 min and precipitated proteins
were removed by centrifugation at 20,000 g for 30 min. (NH4)2SO4 was added slowly to the
supernatant to 65% saturation, and the suspension was stirred for 30 min and centrifuged as
above. Precipitated proteins were resuspended in the volume of buffer B (25 mM sodium
phosphate, pH 6.8, 10% glycerol, 0.5 mM DTT, 0.1 mM PMSF, 1 µg/mL leupeptin, 1 µg/mL
pepstatin) required to produce the equivalent of 0.2 M residual (NH4)2SO4.
Resuspended proteins were applied to a 20 mL hydroxylapatite column (1.5 cm diameter)
that had been equilibrated with buffer C (15 mM sodium phosphate, pH 6.8, 200 mM potassium
phosphate, pH 6.8, 10% glycerol, 0.5 mM DTT, 0.1 mM PMSF, 1 µg/mL leupeptin, 1 µg/mL
pepstatin). The column was washed with three volumes of buffer C and protein was eluted with a
100 mL linear salt gradient from 200 to 750 mM potassium phosphate in buffer C. Fractions
(1.8 mL) were collected and checked for the presence of a 120 kDa protein band by SDSpolyacrylamide gel electrophoresis. Appropriate fractions were pooled, diluted with buffer D
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(15 mM sodium phosphate, pH 6.8, 1 mM EDTA, 1 mM EGTA, 0.5 mM DTT) to a final
potassium phosphate concentration of <200 mM, and applied to a phosphocellulose column (1
mL, 0.7 cm diameter) that had been equilibrated in buffer D that contained 200 mM NaCl.
CVM-1 topoisomerase II was eluted with buffer D that contained 750 mM NaCl. Glycerol was
added to a final concentration of 10% (w/v), and CVM-1 topoisomerase II was aliquoted and
stored in liquid nitrogen. Protein concentrations throughout the purification were determined by
absorbance at 595 nm, using the Bio-Rad Bradford assay kit. For all assays requiring enzyme
dilution, CVM-1 topoisomerase II was freshly diluted in buffer D containing 200 nM NaCl and
40% glycerol.

3

FIGURE S1. CVM-1 topoisomerase II preparation. Samples (1.5 µg) of purified recombinant
CVM-1 topoisomerase II (CVM-1), PBCV-1 topoisomerase II (PBCV-1), and human
topoisomerase IIα (hTIIα) were subjected to electrophoresis on a 7.5% denaturing SDSpolyacrylamide gel and visualized with silver stain. Arrows indicate the electrophoretic mobility
of 200 and 120 kDa molecular weight standards.
FIGURE S2. Optimization of DNA cleavage mediated by CVM-1 topoisomerase II. The effects
of Mg(II) (A), temperature (B), pH (C), and salt (D) on the cleavage of plasmid DNA by CVM-1
topoisomerase II are shown. Cleavage is expressed as the percentage of circular DNA substrate
converted to linear molecules at equilibrium.
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